Press releases https://presse.inserm.fr/en/feed/

Filter

Global Reach: Inserm Celebrates in Washington, DC, 60 Years of Research and Innovation

In celebration of its 60th anniversary, Inserm is emphasizing its scientific collaboration with the United States and Canada. This privileged and fruitful relationship with North America will be highlighted during a day of scientific and institutional exchanges on October 29, 2024, at the French Embassy in Washington, DC. The event will be attended by Professor Didier Samuel, President and CEO of Inserm, along with representatives from numerous partner institutions. The agenda will include the initiation of new collaborations with leading American scientific institutions, the presentation of the 2024 Inserm International Award to a distinguished researcher, the strengthening of Inserm’s...

25 Oct 2024 | Institutionnel et évènementiel

Predominance of zoonotic transmission of the mpox virus in the Democratic Republic of the Congo

Central Africa, especially the Democratic Republic of the Congo (DRC), is highly affected by successive mpox outbreaks. Until now, the extent of genetic diversity of the virus had not been well characterised in this region of the world. For the first time, as part of the AFROSCREEN project and the PANAFPOX project, teams from the Institut National de Recherche Biomédicale (INRB) in DRC, IRD and Inserm have provided important...

24 Oct 2024 | Immunology, inflammation, infectiology and microbiology

Resistance mutations to nirsevimab are rare in respiratory syncytial virus (RSV)

Nirsevimab is an antibody targeting the respiratory syncytial virus (RSV). Available in France since September 2023, it is indicated in neonates and infants for the prevention of bronchiolitis caused by RSV. However, its widespread use raises the question of the emergence of resistance mutations. The POLYRES study, the largest prospective surveillance study of nirsevimab breakthrough infections to date, has just delivered its conclusions. Scientists have shown that nirsevimab resistance...

15 Oct 2024 | Circulation, metabolism, nutrition

Foods with low Nutri-Scores associated with an increased risk of cardiovascular diseases

Researchers from the Nutritional Epidemiology Research Team (CRESS-EREN), with members from Inserm, Inrae, Cnam, Université Sorbonne Paris Nord and Université Paris Cité, in collaboration with researchers from the International Agency for Research on Cancer (WHO-IARC), report an increased risk of cardiovascular diseases associated with the consumption of foods that rank less favourably on the Nutri-Score scale (new 2024 version) within the European cohort EPIC.

11 Sep 2024 | Public health

Ebola: a study in Guinea reveals persistent immunity five years after vaccination

Epidemics of Ebola virus disease occur periodically in several sub-Saharan African countries. Two vaccines have already received WHO prequalification against the Ebolavirus Zaire species. In a new study conducted in Guinea, scientists from VRI, Inserm and Université Paris-Est Créteil (U955 Institut Mondor de recherche biomédicale) have taken a further step in this direction. They have shown that the cellular immune response induced by three different vaccine strategies is...

05 Sep 2024 | Immunology, inflammation, infectiology and microbiology

A Parkinson’s treatment could delay progression of one of the forms of AMD

Age-related macular degeneration (AMD) is the leading cause of visual disability in people over 50 years of age. Improving the treatment offering for patients is a major challenge for research. In a new study, a team of researchers from Inserm, CNRS and Sorbonne Université at the Vision Institute in Paris describes the efficacy of dopaminergic drugs in slowing the progression of one of the forms of the disease, namely...

04 Sep 2024 | Neurosciences, cognitives sciences, neurology and psychiatry

Hepcidin, iron hormone in the skin: a new target in the treatment of psoriasis?

Psoriasis is a chronic inflammatory disease characterised by the rapid and excessive multiplication of skin cells. Although research is progressing and certain treatments are already able to improve the daily lives of patients, this disease remains incurable. The team led by Carole Peyssonnaux, Inserm Research Director at Institut Cochin (Inserm/CNRS/Université Paris Cité) has shown that a hormone that regulates iron in the body, called hepcidin, is produced by the...

03 Sep 2024 | Immunology, inflammation, infectiology and microbiology

Scientists identify immune cells responsible for cancer

Nearly one in three cancers develops following chronic inflammation, whose origin remains unclear. In a new study, researchers from Inserm, CNRS, Université Claude-Bernard Lyon 1 and the Léon Bérard Centre at the Cancer Research Center of Lyon identified lymphocytes involved in the inflammatory processes and that are thought to be implicated in the generation of these cancers. This research opens up new avenues in terms of prevention and treatment.

27 Aug 2024 | Cancer

Rapid rollout of smallpox vaccination reduces the risk of mpox

The ANRS DOXYVAC trial, promoted and funded by ANRS Emerging Infectious Diseases, and conducted by research teams from Inserm, AP-HP, Université Paris Cité and Sorbonne Université (France), shows that a rapid rollout of smallpox vaccination with MVA-BN (Modified vaccine Ankara) among HIV-positive men who have sex with men significantly reduces the risk of mpox by 99%.

12 Aug 2024 | Immunology, inflammation, infectiology and microbiology

Fighting leukaemia by targeting its stem cells

Acute myeloid leukaemia is one of the deadliest cancers. Leukaemic stem cells responsible for the disease are highly resistant to treatment. A team from the University of Geneva (UNIGE), University Hospital of Geneva (HUG), and Inserm has made a breakthrough by identifying some of the genetic and energetic characteristics of these stem cells. Notably, a specific iron utilisation process.

24 Jul 2024 | Cancer

A promising new therapeutic approach for patients with arteriovenous malformations

The teams of the translational medicine and targeted therapies unit of the Necker-Enfants Malades AP-HP hospital, Inserm, Paris Cité University within the Necker–Enfants Malades Institute, coordinated by professors Guillaume Canaud (Université Paris Cité, AP-HP) and Laurent Guibaud (Hospices Civils de Lyon, Reference Center for Superficial Vascular Anomalies), conducted a study showing a promising effect of the anticancer drug sotorasib for arteriovenous malformations secondary to a mutation in the G12C...

18 Jul 2024 | Biologie cellulaire, développement et évolution

fermer